Stock listing

NASDAQ:BDTX Black Diamond Therapeutics, Inc. Stock

Home listing (NASDAQ) of Black Diamond Therapeutics, Inc.

Follow Black Diamond Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BDTX

$1.81 USD +0.09 (+5.2%)

Close on Oct 19, 2026

Past 3 months -8.1% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$1.71 – $1.84 USDOct 19, 2026
Volume
820,838 sharesOct 19, 2026
Market cap
$104.0M USDAt the close on Oct 19, 2026 · price × 57.45M shares outstanding
Black Diamond Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BDTX · Home$1.81 USD+0.09 (+5.2%)820,838$1.71$1.835$1.71$1.72Close on Oct 19, 2026

Daily closes

Last 3 months, Jul 20, 2026 – Oct 19, 2026 · NASDAQ:BDTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.81+0.09+5.2%$1.71$1.835$1.71820,838
$1.72-0.02-1.1%$1.75$1.75$1.675539,751
$1.74+0.04+2.4%$1.69$1.74$1.671614,416
$1.70+0.02+1.2%$1.67$1.76$1.631,068,479
$1.68-0.09-5.1%$1.76$1.77$1.601,135,800
$1.77-0.06-3.3%$1.865$1.865$1.765377,526
$1.83+0.02+1.1%$1.81$1.83$1.79448,966
$1.81-0.02-1.1%$1.81$1.81$1.77784,998
$1.83+0.03+1.7%$1.79$1.87$1.775563,503
$1.80-0.14-7.2%$1.94$1.96$1.795839,100
$1.94+0.05+2.6%$1.90$1.95$1.875838,600
$1.89+0.01+0.5%$1.91$1.94$1.875472,200
$1.88-0.005-0.3%$1.88$1.90$1.84399,100
$1.885+0.015+0.8%$1.89$1.93$1.845551,800
$1.87+0.04+2.2%$1.84$1.89$1.825440,200
$1.83-0.05-2.7%$1.89$1.89$1.81648,300
$1.88-0.01-0.5%$1.91$1.915$1.85378,300
$1.89-0.01-0.5%$1.90$1.915$1.83459,700
$1.90-0.08-4.0%$1.97$1.97$1.85613,500
$1.98+0.03+1.5%$1.93$1.995$1.90743,900
$1.95-0.01-0.5%$1.96$1.97$1.91827,100
$1.96+0.03+1.6%$1.91$1.96$1.911,178,500
$1.93-0.01-0.5%$1.98$2.02$1.92665,300
$1.94-0.03-1.5%$1.97$2.007$1.915733,900
$1.97-0.06-3.0%$2.02$2.02$1.94301,800
$2.03+0.05+2.5%$1.98$2.04$1.97514,100
$1.98+0.02+1.0%$1.99$2.00$1.94589,100
$1.96-0.14-6.7%$2.06$2.06$1.92676,100
$2.100.000.0%$2.09$2.149$2.065402,400
$2.10-0.02-0.9%$2.09$2.13$2.072367,200
$2.12+0.02+1.0%$2.08$2.145$2.061323,700
$2.10-0.04-1.9%$2.15$2.166$2.06609,800
$2.14+0.10+4.9%$2.08$2.155$2.05561,300
$2.04-0.06-2.9%$2.09$2.11$2.02759,100
$2.10-0.13-5.8%$2.22$2.225$2.10507,000
$2.23-0.04-1.8%$2.28$2.29$2.17521,900
$2.270.000.0%$2.26$2.32$2.24457,600
$2.27+0.03+1.3%$2.21$2.29$2.16491,300
$2.24+0.085+3.9%$2.19$2.245$2.185417,500
$2.155-0.055-2.5%$2.22$2.22$2.13345,000
$2.21+0.06+2.8%$2.15$2.26$2.15656,600
$2.15-0.04-1.8%$2.17$2.19$2.081,137,800
$2.19+0.13+6.3%$2.08$2.21$2.08827,000
$2.06+0.01+0.5%$2.05$2.08$2.02474,800
$2.05+0.03+1.5%$2.01$2.085$2.01389,800
$2.020.000.0%$2.01$2.045$1.96330,400
$2.02-0.08-3.8%$2.12$2.12$2.00489,100
$2.10+0.01+0.5%$2.12$2.14$2.02645,500
$2.09+0.11+5.6%$2.01$2.10$1.95812,700
$1.98+0.03+1.5%$1.95$2.02$1.93664,900
$1.95+0.03+1.6%$1.94$1.985$1.905599,900
$1.92+0.13+7.3%$1.80$1.935$1.76748,100
$1.79+0.01+0.6%$1.77$1.825$1.76384,200
$1.78+0.045+2.6%$1.80$1.82$1.735917,200
$1.735+0.045+2.7%$1.73$1.75$1.675429,300
$1.69-0.025-1.5%$1.71$1.71$1.62622,900
$1.715+0.055+3.3%$1.68$1.72$1.65536,100
$1.66-0.10-5.7%$1.76$1.775$1.64869,500
$1.76+0.03+1.7%$1.76$1.77$1.6851,059,300
$1.73-0.03-1.7%$1.77$1.845$1.725625,100
$1.76-0.08-4.3%$1.83$1.83$1.75623,300
$1.84+0.01+0.5%$1.81$1.85$1.80524,400
$1.83-0.04-2.1%$1.86$1.895$1.81520,300
$1.87+0.06+3.3%$1.82$1.88$1.78490,400
$1.81+0.02+1.1%$1.82$1.86$1.77695,800
Ticker
NASDAQ:BDTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Sep 2, 2026

Closed $2.10 (-1.9%) on Sep 3, 2026

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 5, 2026

Closed $1.92 (+7.3%) on Aug 6, 2026

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 19, 2026

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Apr 21, 2026

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 16, 2026

Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer

Jan 28, 2026

Issued by another party

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 3, 2025

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Dec 2, 2025

All Black Diamond Therapeutics, Inc. news

Decks

Black Diamond Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 98 in all · newest Sep 2, 2026 · oldest 2020
Decks
7 decks · latest Dec 3, 2025

Where Black Diamond Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BDTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BDTXBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Black Diamond Therapeutics, Inc.